资讯

GlobalData on MSN11 小时
FDA approves Sanofi and Regeneron’s Dupixent for bullous pemphigoid
The US Food and Drug Administration (FDA) has approved Sanofi and Regeneron’s Dupixent (dupilumab) as a treatment option for ...
FDA approves Dupixent for bullous pemphigoid
The U.S. Food and Drug Administration has approved Dupixent (dupilumab) for the treatment of adult patients with bullous pemphigoid.
The Munich Eye5 小时
FDA Grants Approval for Dupixent to Treat Bullous Pemphigoid
Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.
pharmaphorum20 小时
Sanofi's Dupixent gets FDA nod for chronic hives indication
Sanofi and Regeneron's Dupixent (dupilumab) has been approved by the FDA for the treatment of chronic spontaneous urticaria (CSU), a condition that causes painful hives that often don't respond to ...
Managed Healthcare Executive9 小时
Plans Agree to Prior Auth Reform. Physicians and Business Groups Want Measurable Results
More than 50 insurers have pledged to streamline and simplify the prior authorization process through six new commitments.